Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study.
Fiche du document
- doi: 10.1002/psp4.13032
- issn: 2163-8306
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1002/psp4.13032
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37723920
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2163-8306
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_2BD727D8058F3
info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/
Citer ce document
F. Gaspar et al., « Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study. », Serveur académique Lausannois, ID : 10.1002/psp4.13032
Métriques
Partage / Export
Résumé
This study aimed to characterize apixaban pharmacokinetics (PKs) and its variability in a real-world clinical setting of hospitalized patients using a population PK (PopPK) approach. Model-based simulations helped to identify factors that affect apixaban exposure and their clinical significance. A classic stepwise strategy was applied to determine the best PopPK model for describing typical apixaban PKs in hospitalized patients from the OptimAT study (n = 100) and evaluating the associated variability and influencing factors. Apixaban exposure under specific conditions was assessed using the final model. A two-compartment model with first-order absorption and elimination best described the data. The developed PopPK model revealed a major role of renal function and a minor role of P-glycoprotein phenotypic (P-gp) activity in explaining apixaban variability. The final model indicated that a patient with stage 4 chronic kidney disease (creatinine clearance [CLcr] = 15-29 mL/min) would have a 45% higher drug exposure than a patient with normal renal function (CLcr >90 mL/min), with a further 12% increase if the patient was also a poor metabolizer of P-gp. A high interindividual variability in apixaban PKs was observed in a real-life setting, which was partially explained by renal function and by P-gp phenotypic activity. Target apixaban concentrations are reached under standard dosage regimens, but overexposure can rapidly occur in the presence of cumulative factors warranting the development of a predictive tool for tailoring apixaban exposure and its clinical utility in at-risk patients.